Back

Broadening the scope: should we implement guideline-directed medical therapy across all left ventricular ejection fraction ranges?

18 May 2025 (13:45 - 14:00)
Organised by: Logo
Congress Presentation Part of: Is left ventricular ejection fraction still relevant for guideline-directed medical therapy implementation? Treatment HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Biykem Bozkurt

Baylor College of Medicine, Houston (United States of America)

3 More presentations in this session

Presentation thumbnail
New and emerging therapies for HFpEF
Ms K. Cerlinskaite-Bajore (Vilnius, LT)
Slides Video
Presentation thumbnail
How to approach a patient with HFimpEF
Professor W. Mullens (Genk, BE)
Slides Video
Presentation thumbnail
Is left ventricular ejection fraction still relevant for guideline-directed medical therapy implementation? - discussion
Video

Access the full session

Session thumbnail
Is left ventricular ejection fraction still relevant for guideline-directed medical therapy implementation?
Video

The Event

Event poster

Heart Failure 2025

18 May 2025 13:45 CET
You may be interested in
thumbnail
Congress Presentation
How should we treat HFpEF?
thumbnail
Congress Presentation
State-of-the-art lecture on treatment of HFmrEF and HFpEF in 2023: insights from RCTs
thumbnail
Congress Presentation
Worsening heart failure: optimisation of guideline-recommended medical therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources